ONCOLYTICS

Oncolytics is currently focused on immunotherapy combinations, including in our clinical studies with Bavencio®, Keytruda®, Opdivo®, Tecentriq®, and Retifanlimab... Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. We are currently conducting clinical trials to evaluate pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer.

Also known as: Oncolytics Biotech, Oncolytics Biotech (U.S.) Inc., Oncolytics Biotech, Inc.

Primary location: Calgary